Abstract：
Aclarubicin (aclacinomycin A) is one of the anthracycline antineoplastic antibiotics with a multifaceted mechanism of antitumor activity. As a second-generation drug, it offers several advantages compared to standard anthracycline drugs such as doxorubicin or daunorubicin, which could position it as a potential blockbuster drug in antitumor therapy. Key mechanisms of action for aclarubicin include the inhibition of both types of topoisomerases, suppression of tumor invasion processes, generation of reactive oxygen species, inhibition of chymotrypsin-like activity, influence on cisplatin degradation, and inhibition of angiogenesis. Therefore, aclarubicin appears to be an ideal candidate for antitumor therapy. However, despite initial interest in its clinical applications, only a limited number of high-quality trials have been conducted thus far. Aclarubicin has primarily been evaluated as an induction therapy in acute myeloid and lymphoblastic leukemia. Studies have indicated that aclarubicin may hold significant promise for combination therapies with other anticancer drugs, although further research is needed to confirm its potential. This paper provides an in-depth exploration of aclarubicin\'s diverse mechanisms of action, its pharmacokinetics, potential toxicity, and the clinical trials in which it has been investigated.
摘要：
阿克拉霉素（aclacinomycinA）是蒽环类抗肿瘤抗生素之一，具有多方面的抗肿瘤活性机制。作为第二代药物，与阿霉素或柔红霉素等标准蒽环类药物相比，它具有多种优势，这可能将其定位为抗肿瘤治疗中的潜在重磅药物。阿克拉霉素的主要作用机制包括抑制两种类型的拓扑异构酶，抑制肿瘤侵袭过程，产生活性氧，抑制胰凝乳蛋白酶样活性，对顺铂降解的影响，和抑制血管生成。因此,阿克拉比星似乎是抗肿瘤治疗的理想候选者。然而,尽管最初对其临床应用感兴趣，到目前为止,仅进行了数量有限的高质量试验.阿克拉比星主要被评估为急性骨髓性和淋巴母细胞性白血病的诱导疗法。研究表明，阿克拉霉素可能与其他抗癌药物联合治疗具有重要的前景，尽管需要进一步的研究来证实其潜力。本文对阿克拉霉素的多种作用机制进行了深入的探索,其药代动力学，潜在毒性,以及对其进行研究的临床试验。
